Bvf Inc 89bio, Inc. Transaction History

Bvf Inc

$3.27 Billion
Q2 2024

A detailed history of Bvf Inc transactions in 89bio, Inc. stock. As of the latest transaction made, Bvf Inc holds 7,568,479 shares of ETNB stock, worth $75.5 Million. This represents 1.85% of its overall portfolio holdings.

Number of Shares

7,568,479

Previous 4,047,354 87.0%

Holding current value

$75.5 Million

Previous $47.1 Million 28.68%

% of portfolio

1.85%

Previous 1.41%

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$7.31 - $10.9 $25.7 Million - $38.4 Million	3,521,125 Added 87.0%	7,568,479 $60.6 Million
Q4 2023 Feb 14, 2024	BUY	$6.66 - $16.03 $14.7 Million - $35.3 Million	2,201,200 Added 119.23%	4,047,354 $45.2 Million
Q1 2023 May 15, 2023	BUY	$10.48 - $16.94 $19.3 Million - $31.3 Million	1,846,154 New	1,846,154 $28.1 Million
Q3 2022 Nov 14, 2022	SELL	$3.02 - $7.0 $2.28 Million - $5.28 Million	-754,318 Reduced 19.35%	3,143,682 $18.2 Million
Q2 2022 Aug 15, 2022	BUY	$2.09 - $4.02 $8.15 Million - $15.7 Million	3,898,000 New	3,898,000 $12.6 Million

Others Institutions Holding ETNB

# of Institutions

157

Shares Held

107M

Call Options Held

65K

Put Options Held

1.2M

View Full List

About 89bio, Inc.

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $463M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

More about ETNB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bvf Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bvf Inc with notifications on news.

Account